Literature DB >> 17785551

Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells.

Gregory B Lesinski1, John Trefry, Melanie Brasdovich, Sri Vidya Kondadasula, Korkor Sackey, Jason M Zimmerer, Abhik Ray Chaudhury, Lianbo Yu, Xiaoli Zhang, Tim R Crespin, Michael J Walker, William E Carson.   

Abstract

PURPOSE: IFN-alpha is administered to melanoma patients and its endogenous production is essential for immune-mediated tumor recognition. We hypothesized that a reduced capacity for signal transducer and activator of transcription (STAT) 1 activation allows melanoma cells to evade the direct actions of IFN-alpha. EXPERIMENTAL
DESIGN: Tyr(701)-phosphorylated STAT1 (P-STAT1) was measured by flow cytometry in IFN-alpha-stimulated human melanoma cell lines, melanoma cells derived from patient tumors, and peripheral blood mononuclear cells (PBMC). Expression of other Janus-activated kinase (Jak)-STAT intermediates (STAT1, STAT2, Jak1, tyrosine kinase 2, IFN-alpha receptor, STAT3, and STAT5) was evaluated by flow cytometry, immunoblot, or immunohistochemistry.
RESULTS: Significant variability in P-STAT1 was observed in human melanoma cell lines following IFN-alpha treatment (P < 0.05) and IFN-alpha-induced P-STAT1 correlated with the antiproliferative effects of IFN-alpha (P = 0.042). Reduced formation of P-STAT1 was not explained by loss of Jak-STAT proteins or enhanced STAT5 signaling as reported previously. Basal levels of P-STAT3 were inversely correlated with IFN-alpha-induced P-STAT1 in cell lines (P = 0.013). IFN-alpha-induced formation of P-STAT1 was also variable in melanoma cells derived from patient tumors; however, no relationship between P-STAT3 and IFN-alpha-induced P-STAT1 was evident. Because IFN-alpha acts on both tumor and immune cells, we examined the ability of IFN-alpha to induce P-STAT1 in patient-derived melanoma cells and PBMCs. IFN-alpha induced significantly lower levels of P-STAT1 in melanoma cells compared with matched PBMCs (P = 0.046). Melanoma cells and human melanocytes required 10-fold higher IFN-alpha doses to exert P-STAT1 levels comparable with PBMCs.
CONCLUSIONS: Melanoma cells are variable in their IFN-alpha responsiveness, and cells of the melanocytic lineage exhibit a lower capacity for IFN-alpha-induced Jak-STAT signaling compared with immune cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17785551     DOI: 10.1158/1078-0432.CCR-06-3092

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  21 in total

1.  Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2.

Authors:  Hla Win-Piazza; Valentina E Schneeberger; Liwei Chen; Daniele Pernazza; Harshani R Lawrence; Said M Sebti; Nicholas J Lawrence; Jie Wu
Journal:  Cancer Lett       Date:  2012-02-01       Impact factor: 8.679

2.  Contrasting effects of IFNα on MHC class II expression in professional vs. nonprofessional APCs: Role of CIITA type IV promoter.

Authors:  Laura Pisapia; Giovanna Del Pozzo; Pasquale Barba; Alessandra Citro; Paul E Harris; Antonella Maffei
Journal:  Results Immunol       Date:  2012-09-27

3.  IRF9 is a key factor for eliciting the antiproliferative activity of IFN-alpha.

Authors:  Takaya Tsuno; Josef Mejido; Tongmao Zhao; Hana Schmeisser; Angel Morrow; Kathryn C Zoon
Journal:  J Immunother       Date:  2009-10       Impact factor: 4.456

4.  Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma.

Authors:  Megan C Duggan; Andrew R Stiff; Maryam Bainazar; Kelly Regan; Gonzalo N Olaverria Salavaggione; Sophia Maharry; James S Blachly; Madison Krischak; Christopher J Walker; Nicholas Latchana; Susheela Tridandapani; Albert de la Chapelle; Ann-Kathrin Eisfeld; William E Carson
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-21       Impact factor: 11.205

5.  Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy.

Authors:  Bethany L Mundy-Bosse; Gregory S Young; Todd Bauer; Elaine Binkley; Mark Bloomston; Matthew A Bill; Tanios Bekaii-Saab; William E Carson; Gregory B Lesinski
Journal:  Cancer Immunol Immunother       Date:  2011-05-21       Impact factor: 6.968

6.  Enhanced anti-melanoma efficacy of interferon α-2b via overexpression of ING4 by enhanced Fas/FasL-mediated apoptosis.

Authors:  Limin Cai; Jing Liu; Yu Wang; Hongxiao Chen; Yanli Ma; Yanhua Wang; Yongchen Wang
Journal:  Oncol Lett       Date:  2018-04-18       Impact factor: 2.967

7.  Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.

Authors:  Bethany L Mundy-Bosse; Gregory B Lesinski; Alena C Jaime-Ramirez; Kristen Benninger; Mahmood Khan; Periannan Kuppusamy; Kristan Guenterberg; Sri Vidya Kondadasula; Abhik Ray Chaudhury; Krista M La Perle; Melanie Kreiner; Gregory Young; Denis C Guttridge; William E Carson
Journal:  Cancer Res       Date:  2011-06-16       Impact factor: 12.701

8.  Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells.

Authors:  Gregory B Lesinski; Jason M Zimmerer; Melanie Kreiner; John Trefry; Matthew A Bill; Gregory S Young; Brian Becknell; William E Carson
Journal:  BMC Cancer       Date:  2010-04-14       Impact factor: 4.430

9.  The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity.

Authors:  Matthew A Bill; James R Fuchs; Chenglong Li; Jennifer Yui; Courtney Bakan; Don M Benson; Eric B Schwartz; Dalia Abdelhamid; Jiayuh Lin; Dale G Hoyt; Stacey L Fossey; Gregory S Young; William E Carson; Pui-Kai Li; Gregory B Lesinski
Journal:  Mol Cancer       Date:  2010-06-25       Impact factor: 27.401

10.  Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells.

Authors:  Gregory B Lesinski; Kristen Benninger; Melanie Kreiner; Megan Quimper; Gregory Young; William E Carson
Journal:  Cancer Immunol Immunother       Date:  2009-04-26       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.